1
|
Kirita K, Futagami S, Nakamura K, Agawa S, Ueki N, Higuchi K, Habiro M, Kawawa R, Kato Y, Tada T, Iwakiri K. Combination of artificial intelligence endoscopic diagnosis and Kimura-Takemoto classification determined by endoscopic experts may effectively evaluate the stratification of gastric atrophy in post-eradication status. DEN OPEN 2025; 5:e70029. [PMID: 39534404 PMCID: PMC11555298 DOI: 10.1002/deo2.70029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Revised: 10/07/2024] [Accepted: 10/08/2024] [Indexed: 11/16/2024]
Abstract
Background Since it is difficult for expert endoscopists to diagnose early gastric cancer in post-eradication status, it may be critical to evaluate the stratification of high-risk groups using the advance of gastric atrophy or intestinal metaplasia. We tried to determine whether the combination of endoscopic artificial intelligence (AI) diagnosis for the evaluation of gastric atrophy could be a useful tool in both pre- and post-eradication status. Methods 270 Helicobacter pylori-positive outpatients (Study I) were enrolled and Study II was planned to compare patients (n = 72) with pre-eradication therapy with post-eradication therapy. Assessment of endoscopic appearance was evaluated by the Kyoto classification and Kimura-Takemoto classification. The trained neural network generated a continuous number between 0 and 1 for gastric atrophy. Results There were significant associations between the severity of gastric atrophy determined by AI endoscopic diagnosis and not having a regular arrangement of collecting venules in angle, visibility of vascular pattern, and mucus using Kyoto classification in H. pylori-positive gastritis. There were significant differences (p = 0.037 and p = 0.014) in the severity of gastric atrophy between the high-risk group and low-risk group based on the combination of Kimura-Takemoto classification and endoscopic AI diagnosis in pre- and post-eradication status. The area under the curve values of the severity of gastric atrophy (0.674) determined by the combination of Kimura-Takemoto classification and gastric atrophy determined by AI diagnosis was higher than that determined by Kimura-Takemoto classification alone in post-eradication status. Conclusion A combination of gastric atrophy determined by AI endoscopic diagnosis and Kimura-Takemoto classification may be a useful tool for the prediction of high-risk groups in post-eradication status.
Collapse
Affiliation(s)
- Kumiko Kirita
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Seiji Futagami
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Ken Nakamura
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Shuhei Agawa
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Nobue Ueki
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Kazutoshi Higuchi
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Mayu Habiro
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | - Rie Kawawa
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| | | | | | - Katsuhiko Iwakiri
- Department of GastroenterologyNippon Medical School HospitalGraduate School of MedicineTokyoJapan
| |
Collapse
|
2
|
Akyüz F, An YK, Begun J, Aniwan S, Bui HH, Chan W, Choi CH, Chopdat N, Connor SJ, Desai D, Flanagan E, Kobayashi T, Lai AYH, Leong RW, Leow AHR, Leung WK, Limsrivilai J, Muzellina VN, Peddi K, Ran Z, Wei SC, Sollano J, Teo MMH, Wu K, Ye BD, Ooi CJ. Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intest Res 2025; 23:37-55. [PMID: 39492666 PMCID: PMC11834365 DOI: 10.5217/ir.2024.00089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Revised: 08/08/2024] [Accepted: 08/09/2024] [Indexed: 11/05/2024] Open
Abstract
The lack of clear definition and classification for "moderate ulcerative colitis (UC)" creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.
Collapse
Affiliation(s)
- Filiz Akyüz
- Department of Gastroenterology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
| | - Yoon Kyo An
- Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Australia
| | - Jakob Begun
- Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Australia
| | - Satimai Aniwan
- Division of Gastroenterology, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
| | - Huu Hoang Bui
- Department of Gastroenterology, University Medical Center, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam
| | - Webber Chan
- The Gastroenterology Group, Gleneagles Hospital, Singapore
| | - Chang Hwan Choi
- Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
| | - Nazeer Chopdat
- Department of Gastroenterology, Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa
| | - Susan J Connor
- Department of Gastroenterology, Liverpool Hospital, Sydney, Australia
- South Western Clinical School, University of New South Wales, Sydney, Australia
| | - Devendra Desai
- Division of Medical Gastroenterology, P. D. Hinduja Hospital, Mumbai, India
| | - Emma Flanagan
- Department of Gastroenterology, St. Vincent’s Hospital, Melbourne, Australia
| | - Taku Kobayashi
- Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
| | - Allen Yu-Hung Lai
- Global Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan
- Ferring Pharmaceuticals, Singapore
| | - Rupert W Leong
- Department of Gastroenterology, Concord Hospital, Sydney, Australia
| | | | - Wai Keung Leung
- Department of Medicine, University of Hong Kong, Hong Kong, China
| | - Julajak Limsrivilai
- Deparment of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Virly Nanda Muzellina
- Gastrointestinal Endoscopy Center, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
- Universitas Indonesia, Jakarta, Indonesia
| | - Kiran Peddi
- Department of Gastroenterology, Yashoda Hospital, Hyderabad, India
| | - Zhihua Ran
- Department of Gastroenterology, Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, China
| | - Shu Chen Wei
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Jose Sollano
- Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines
| | | | - Kaichun Wu
- Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
| | - Byong Duk Ye
- Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | | |
Collapse
|
3
|
Bakkaloglu OK, Sen G, Kepil N, Eskazan T, Kurt EA, Onal U, Candan S, Balamir M, Hatemi I, Erzin Y, Celik AF. Comparative Value of CRP and FCP for Endoscopic and Histologic Remissions in Ulcerative Colitis. Diagnostics (Basel) 2024; 14:2283. [PMID: 39451607 PMCID: PMC11506680 DOI: 10.3390/diagnostics14202283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2024] [Revised: 08/21/2024] [Accepted: 08/27/2024] [Indexed: 10/26/2024] Open
Abstract
Aim: We have previously shown that CRP < 2.9 mg/L is a better predictor of endoscopic remission (ER) than CRP < 5 mg/L in ulcerative colitis (UC). Here, we prospectively evaluate CRP and FCP cut-offs and compare them in predicting ER and histological remission (HR) in UC. Method: One hundred thirty-five steroid-free UC patients were evaluated prospectively. ER was defined as Mayo endoscopic sub-score 0-1. In colonoscopy, the colon was evaluated as seven segments: rectum, sigmoid, descending, proximal-transverse, distal-transverse, ascending colon, and cecum. Two biopsies of each segment were evaluated for histological inflammation and graded using the Nancy and Geboes scores. All segment biopsies with Nancy < 1 and Geboes < 2 were defined as HR. Results: The optimum cut-off values for FCP and CRP were 120 μg/g and 2.75 mg/L for ER, respectively. AUC values of FCP and CRP were similar for ER and Mayo-0 disease in ROC analysis. CRP and FCP also had similar performances with these cut-offs regarding ER. While CRP was a predictor to assess the extensiveness of active UC, FCP was not. ROC analysis showed no difference between CRP and FCP regarding HR. Cut-off values for HR were 2.1 mg/L and 55 μg/g for CRP and FCP, respectively. CRP and FCP, in combination with the mentioned cut-off values, detected ER and HR in nearly 2/3 and ½ of the patients, respectively, with high specificity. Conclusions: Reappraised CRP (ER: 2.75 mg/L, HR: 2.1 mg/L) has as much diagnostic contribution as relevant FCP in predicting ER and HR and contributes more to revealing the proximal extension in active colitis compared to FCP. Relevant CRP and FCP combinations may improve the prediction rates.
Collapse
Affiliation(s)
- Oguz Kagan Bakkaloglu
- Department of Gastroenterology, Kartal Kosuyolu High Specialization Education and Research Hospital, 34865 Istanbul, Turkey
| | - Gozde Sen
- Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Nuray Kepil
- Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Tugce Eskazan
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Enes Ali Kurt
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Ugur Onal
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Selcuk Candan
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Melek Balamir
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Ibrahim Hatemi
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Yusuf Erzin
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| | - Aykut Ferhat Celik
- Department of Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University Cerrahpasa, 34098 Istanbul, Turkey
| |
Collapse
|
4
|
Rykina-Tameeva N, Samra JS, Sahni S, Mittal A. Drain fluid biomarkers for prediction and diagnosis of clinically relevant postoperative pancreatic fistula: A narrative review. World J Gastrointest Surg 2022; 14:1089-1106. [PMID: 36386401 PMCID: PMC9640330 DOI: 10.4240/wjgs.v14.i10.1089] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 09/16/2022] [Accepted: 10/14/2022] [Indexed: 02/07/2023] Open
Abstract
Clinically relevant postoperative pancreatic fistula (CR-POPF) has continued to compromise patient recovery post-pancreatectomy despite decades of research seeking to improve risk prediction and diagnosis. The current diagnostic criteria for CR-POPF requires elevated drain fluid amylase to present alongside POPF-related complications including infection, haemorrhage and organ failure. These worrying sequelae necessitate earlier and easily obtainable biomarkers capable of reflecting evolving CR-POPF. Drain fluid has recently emerged as a promising source of biomarkers as it is derived from the pancreas and hence, capable of reflecting its postoperative condition. The present review aims to summarise the current knowledge of CR-POPF drain fluid biomarkers and identify gaps in the field to invigorate future research in this critical area of clinical need. These findings may provide robust diagnostic alternatives for CR-POPF and hence, to clarify their clinical utility require further reports detailing their diagnostic and/or predictive accuracy.
Collapse
Affiliation(s)
| | - Jaswinder S Samra
- Northern Clinical School, University of Sydney, St Leonards 2065, Australia
| | - Sumit Sahni
- Northern Clinical School, University of Sydney, St Leonards 2065, Australia
| | - Anubhav Mittal
- Northern Clinical School, University of Sydney, St Leonards 2065, Australia
| |
Collapse
|
5
|
Eley C, Hawkes ND, Egan RJ, Robinson DB, Brown C, Murray S, Siau K, Lewis W. Face validity of a virtual reality simulation platform to improve competency in endoscopy: a prospective observational cohort study. Endosc Int Open 2022; 10:E1218-E1224. [PMID: 36118643 PMCID: PMC9473829 DOI: 10.1055/a-1882-4246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Accepted: 06/08/2022] [Indexed: 11/30/2022] Open
Abstract
Background and study aims Virtual reality endoscopic simulation training has the potential to expedite competency development in novice trainees. However, simulation platforms must be realistic and confer face validity. This study aimed to determine the face validity of high-fidelity virtual reality simulation (EndoSim, Surgical Science, Gothenburg), and establish benchmark metrics to guide the development of a Simulation Pathway to Improve Competency in Endoscopy (SPICE). Methods A pilot cohort of four experts rated simulated exercises (Likert scale score 1-5) and following iterative development, 10 experts completed 13 simulator-based endoscopy exercises amounting to 859 total metric values. Results Expert metric performance demonstrated equivalence ( P = 0.992). In contrast, face validity of each exercise varied among experts (median 4 (interquartile range [IQR] 3-5), P < 0.003) with Mucosal Examination receiving the highest scores (median 5 [IQR 4.5-5], P = 1.000) and Loop Management and Intubation exercises receiving the lowest scores (median 3 [IQR 1-3], P < 0.001, P = 0.004), respectively. The provisional validated SPICE comprised 13 exercises with pass marks and allowance buffers defined by median and IQR expert performance. Conclusions EndoSim Face Validity was very good related to early scope handling skills, but more advanced competencies and translation of acquired clinical skills require further research within an established training program. The existing training deficit with superadded adverse effects of the COVID pandemic make this initiative an urgent priority.
Collapse
Affiliation(s)
- Catherine Eley
- Health Education and Improvement Wales. Ty Dysgu, Cefn Coed, Nantgarw, UK
| | | | - Richard J Egan
- Morriston Hospital, Heol Maes Eglwys, Morriston, Swansea, UK
- Swansea University, Singleton Park, Sketty, Swansea, UK
| | - David B Robinson
- Health Education and Improvement Wales. Ty Dysgu, Cefn Coed, Nantgarw, UK
| | - Chris Brown
- Health Education and Improvement Wales. Ty Dysgu, Cefn Coed, Nantgarw, UK
- Morriston Hospital, Heol Maes Eglwys, Morriston, Swansea, UK
| | - Sam Murray
- Southmead Hospital, Southmead Road, Bristol, UK
| | - Keith Siau
- Royal Cornwall Hospitals NHS Trust, Truro, UK
| | - Wyn Lewis
- Health Education and Improvement Wales. Ty Dysgu, Cefn Coed, Nantgarw, UK
| |
Collapse
|
6
|
Grossi U, Gallo G, Di Tanna GL, Bracale U, Ballo M, Galasso E, Kazemi Nava A, Zucchella M, Cinetto F, Rattazzi M, Felice C, Zanus G. Surgical Management of Hemorrhoidal Disease in Inflammatory Bowel Disease: A Systematic Review with Proportional Meta-Analysis. J Clin Med 2022; 11:709. [PMID: 35160159 PMCID: PMC8837177 DOI: 10.3390/jcm11030709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 01/25/2022] [Accepted: 01/27/2022] [Indexed: 02/06/2023] Open
Abstract
Surgical treatment of hemorrhoidal disease (HD) in inflammatory bowel disease (IBD) has been considered to be potentially harmful, but the evidence for this is poor. Therefore, a systematic review of the literature was undertaken to reappraise the safety and effectiveness of surgical treatments in this special circumstance. A MEDLINE, Web of Science, Scopus, and Cochrane Library search was performed to retrieve studies reporting the outcomes of surgical treatment of HD in patients with Crohn's disease (CD) and ulcerative colitis (UC). From a total of 2072 citations, 10 retrospective studies including 222 (range, 2-70) patients were identified. Of these, 119 (54%) had CD and 103 (46%) UC. Mean age was between 41 and 49 years (range 14-77). Most studies lacked information on the interval between surgery and the onset of complications. Operative treatments included open or closed hemorrhoidectomy (n = 156 patients (70%)), rubber band ligation (n = 39 (18%)), excision or incision of thrombosed hemorrhoid (n = 14 (6%)), and doppler-guided hemorrhoidal artery ligation (DG-HAL, n = 13 (6%)). In total, 23 patients developed a complication (pooled prevalence, 9%; (95%CI, 3-16%)), with a more than two-fold higher rate in patients with CD compared to UC (11% (5-16%) vs. 5% (0-13%), respectively). Despite the low quality evidence, surgical management of HD in IBD and particularly in CD patients who have failed nonoperative therapy should still be performed with caution and limited to inactive disease. Further studies should determine whether advantages in terms of safety and effectiveness with the use of non-excisional techniques (e.g., DG-HAL) can be obtained in this patient population.
Collapse
Affiliation(s)
- Ugo Grossi
- II Surgery Unit, Regional Hospital Treviso, AULSS2, 31100 Treviso, Italy; (M.B.); (E.G.); (A.K.N.); (M.Z.); (G.Z.)
- Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, 35128 Padua, Italy
| | - Gaetano Gallo
- Department of Medicine, Surgery and Neurosciences, Unit of General Surgery and Surgical Oncology, University of Siena, 53100 Siena, Italy;
| | - Gian Luca Di Tanna
- Statistics Division, The George Institute for Global Health, University of New South Wales, Sydney 2042, Australia;
| | - Umberto Bracale
- Department of Advanced Biomedical Sciences, ‘Federico II’ University of Naples, 80131 Naples, Italy;
| | - Mattia Ballo
- II Surgery Unit, Regional Hospital Treviso, AULSS2, 31100 Treviso, Italy; (M.B.); (E.G.); (A.K.N.); (M.Z.); (G.Z.)
- Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, 35128 Padua, Italy
| | - Elisa Galasso
- II Surgery Unit, Regional Hospital Treviso, AULSS2, 31100 Treviso, Italy; (M.B.); (E.G.); (A.K.N.); (M.Z.); (G.Z.)
- Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, 35128 Padua, Italy
| | - Andrea Kazemi Nava
- II Surgery Unit, Regional Hospital Treviso, AULSS2, 31100 Treviso, Italy; (M.B.); (E.G.); (A.K.N.); (M.Z.); (G.Z.)
| | - Martino Zucchella
- II Surgery Unit, Regional Hospital Treviso, AULSS2, 31100 Treviso, Italy; (M.B.); (E.G.); (A.K.N.); (M.Z.); (G.Z.)
| | - Francesco Cinetto
- Department of Medicine-DIMED, University of Padua, 35128 Padua, Italy; (F.C.); (M.R.); (C.F.)
| | - Marcello Rattazzi
- Department of Medicine-DIMED, University of Padua, 35128 Padua, Italy; (F.C.); (M.R.); (C.F.)
| | - Carla Felice
- Department of Medicine-DIMED, University of Padua, 35128 Padua, Italy; (F.C.); (M.R.); (C.F.)
| | - Giacomo Zanus
- II Surgery Unit, Regional Hospital Treviso, AULSS2, 31100 Treviso, Italy; (M.B.); (E.G.); (A.K.N.); (M.Z.); (G.Z.)
- Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, 35128 Padua, Italy
| |
Collapse
|